This study estimated the additional costs and effectiveness of Option B+ through a deterministic model to simulate births, breastfeeding, and HIV infection in women in four countries, Kenya, Zambia, South Africa, and Vietnam. Findings showed that Option B+ was the most cost-effective strategy costing between $6000 and $23 000 per infection averted compared with Option A. [read more …]
Publications for Option B Plus
Women’s Preferences Regarding Infant or Maternal Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission of HIV during Breastfeeding and Their Views on Option B+ in Dar es Salaam, Tanzania.
A qualitative study was conducted in Dar es Salaam, Tanzania to explore women’s preferences for Option A versus B for PMTCT and their views on Option B+. Focused group discussions were conducted with 27 pregnant women with unknown HIV status and 31 HIV-infected pregnant and postpartum women. Findings showed that most participant preferred Option B [read more …]
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
This study was conducted among a cohort of HIV infected pregnant women from the DREAM Center in Nairobi, Kenya. The study was to evaluate the effectiveness of Highly Active Antiretroviral Therapy (HAART) in prevention of mother to child transmission of HIV (PMTCT). It was found that the mean absolute CD4 cell count in mothers after [read more …]
Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach.
In a review of evidences for initiation of lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women both benefits and risks were identified. Some of the benefits include PMTCT program simplicity in terms of feasibility, access, uptake, and retention in care and being cost-effective in a long run. The safety of ART exposure to [read more …]